Title:Selenium-Derivative Compounds: A Review of New Perspectives in
the Treatment of Alzheimer’s Disease
Volume: 30
Issue: 6
Author(s): Flavio A.R. Barbosa, Rômulo F.S. Canto, Kerolain F. Teixeira, Anacleto S. de Souza, Aldo S. de Oliveira*Antonio L. Braga*
Affiliation:
- Department of Exact Sciences and Education, Federal University of Santa Catarina, Blumenau-SC, Brazil.
- Department of Chemistry, Center for Physical and Mathematical Sciences, Federal University of Santa Catarina, Florianópolis-SC, Brazil
- Department of Chemical Sciences, Faculty of Science, University of Johannesburg, Doornfontein, South Africa.
Keywords:
Organoselenium, Alzheimer’s disease, multi-targeted drugs, antioxidant, GPx, selenium.
Abstract:
Background: Alzheimer’s disease (AD) is one of the most prevalent types of
dementia, affecting millions of older people worldwide. AD is stimulating efforts to develop
novel molecules targeting its main features associated with a decrease in acetylcholine
levels, an increase in oxidative stress and depositions of amyloid-β (Aβ) and tau protein.
In this regard, selenium-containing compounds have been demonstrated as potential
multi-targeted compounds in the treatment of AD. These compounds are known for their
antioxidant and anticholinesterase properties, causing a decrease in Aβ aggregation.
Objective: In this review, we approach structure-activity relationships of each compound,
associating the decrease of ROS activity, an increase of tau-like activity and inhibition of
AChE with a decrease in the self-aggregation of Aβ.
Methods: We also verify that the molecular descriptors apol, nHBAcc and MlogP may
be related to optimized pharmacokinetic properties for anti-AD drugs.
Results: In our analysis, few selenium-derived compounds presented similar molecular
features to FDA-approved drugs.
Conclusion: We suggest that unknown selenium-derived molecules with apol, nHBAcc
and MlogP like FDA-approved drugs may be better successes with optimized pharmacokinetic
properties in future studies in AD.
